Business Context and Reporting Period
This Form 8-K was filed by Biorestorative Therapies, Inc. on November 23, 2016, reporting events occurring between October 19, 2016, and January 25, 2017. The filing details unregistered sales of equity securities under Item 3.02.
Key Financial Metrics and Capital Activities
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. Instead, it reports specific capital raising and debt settlement activities:
- Equity Issuance for Cash: Issued 236,656 shares of common stock at $3.00 per share between November 9, 2016, and January 25, 2017.
- Warrants Issued: Granted five-year warrants to purchase 246,656 shares at an exercise price of $4.00 per share in connection with the equity issuance.
- Debt Settlement: Issued 21,389 shares of common stock between November 7, 2016, and November 22, 2016, to settle $42,186 of outstanding indebtedness (including accrued interest).
- Stock for Services: Issued 7,500 shares on October 19, 2016, valued at $15,000, in consideration for services rendered.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The material change reported is the dilution of existing shareholders through the issuance of approximately 265,545 new shares and the reduction of $42,186 in debt obligations.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the unregistered nature of the securities. The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, asserting that no general solicitation was used and that investors were accredited.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the current status of the $42,186 debt settlement and whether any residual liability remains.
- Review the terms of the five-year warrants (exercise price $4.00) to evaluate potential future dilution.
- Check subsequent filings for the actual cash proceeds received from the $3.00 per share offering.